dr. jotte on the impower131 findings in squamous nsclc
Published 6 years ago • 257 plays • Length 2:11Download video MP4
Download video MP3
Similar videos
-
0:38
copy of dr. jotte on the low rate of screening in lung cancer
-
1:25
dr. jotte on the optimal frequency of lung cancer screening
-
9:15
chemo/immunotherapy in advanced squamous nsclc: what is the impact of impower131? (bmic-026)
-
8:10
impower131: role for carbo/nab-paclitaxel/atezolizumab combo for adv. squamous nsclc? (bmic-041)
-
1:05
dr. brahmer on the impower150 trial in nsclc
-
1:16
dr herbst on the evolution of egfr inhibition in lung cancer
-
50:54
lung cancer screening, diagnosis, and treatment for the primary care provider
-
2:15
dr. wakelee on birch trial for atezolizumab in patients with nsclc
-
1:35
dr. herbst on the benefit of adjuvant osimertinib in egfr-mutant nsclc
-
1:56
dr. herbst on advances of immunotherapy in lung cancer
-
1:37
dr. zhang on the imvigor130 trial in metastatic urothelial cancer
-
12:33
priority review in squamous nsclc, european recommendations across tumor types, and more
-
1:35
dr. kim discusses the primary efficacy results from b-f1rst in nsclc
-
7:29
blood-based tmb as a predictive biomarker in nsclc
-
1:02
dr. herbst on pd-1 inhibitors in lung cancer
-
1:07
dr. nanus on next steps with atezolizumab in patients with muc
-
1:26
dr. oxnard on the role of osimertinib in the tatton trial for lung cancer
-
1:16
germline testing in urothelial cancer
-
0:20
preview: dr. gainor on clinical trials